Back to Devoured - November 13, 2026
DEVOURED
The Next Chapter of mRNA

The Next Chapter of mRNA

Tech Time
Moderna is shifting its focus to an mRNA platform for oncology and rare diseases following the success of its COVID-19 vaccine.
What: CEO Stéphane Bancel reports positive results for the melanoma vaccine intismeran, which reduced recurrence by 42% in trials conducted with Merck's Keytruda, despite regulatory and financial headwinds during the second Trump administration.
Why it matters: This indicates a transition in biotechnology from traditional drug discovery to a platform-based engineering model where mRNA acts as an information molecule to instruct cellular protein production.
Deep dive
  • Moderna's intismeran vaccine uses a personalized mRNA sequence targeting 34 tumor mutations.
  • The development process relies on rapid genetic sequencing and computational analysis rather than traditional cell culture growth.
  • The company faced significant financial setbacks after a $766 million federal contract was canceled in May 2025.
  • Moderna plans to file for FDA approval of intismeran for melanoma in 2027.
Decoder
  • mRNA: Messenger RNA, the molecule that carries genetic instructions to cells to produce specific proteins.
  • Checkpoint inhibitor: A type of immunotherapy that blocks proteins used by cancer cells to hide from the immune system, such as Merck's Keytruda.
  • Recombinant DNA technology: Traditional biotechnology where DNA is modified to cause bacteria or viruses to produce specific therapeutic proteins.
Original article

Full article content is not available for inline reading.

Read the original article →

Explore all 57 articles in today's digest

Fresh dev news, AI-digested daily. Never miss a trend at devoured.fyi